Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39363   clinical trials with a EudraCT protocol, of which   6448   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-000148-14
    Sponsor's Protocol Code Number:PLX108-10
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-01-13
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-000148-14
    A.3Full title of the trial
    A double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN
    Studio di fase III randomizzato, in doppio cieco, controllato con placebo, su PLX3397 per via orale in soggetti con sinovite villonodulare pigmentosa o tumore a cellule giganti delle guaine tendinee ENLIVEN
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical Trial comparing the effectiveness of PLX3397 against placebo in the treatment of Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN
    Sudio clinico per comparare l'efficacia di PLX3397 verso il placebo nel trattamento della sinovite villonodulare pigmentosa o tumore a cellule giganti delle guainee tendinee ENLIVEN
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberPLX108-10
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02371369
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDAIICHI SANKYO INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDaiichi Sankyo Pharma Development
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportDaiichi Sankyo Company, Limited
    B.4.2CountryJapan
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDaiichi Sankyo Inc
    B.5.2Functional name of contact pointClinical Trial Information contact
    B.5.3 Address:
    B.5.3.1Street Address399 Thornall Street
    B.5.3.2Town/ cityEDISON
    B.5.3.3Post codeNJ 08837
    B.5.3.4CountryUnited States
    B.5.4Telephone number0017325905000
    B.5.5Fax number0017329065690
    B.5.6E-maileu_cta@dsi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/279/14
    D.3 Description of the IMP
    D.3.1Product namePLX3397
    D.3.2Product code PLX3397
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpexidartinib cloridrato
    D.3.9.1CAS number 1029044-16-3
    D.3.9.2Current sponsor codePLX3397
    D.3.9.3Other descriptive namePexidartinib
    D.3.9.4EV Substance CodeSUB33175
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pigmented villonodular synovitis (PVNS) / giant cell tumor of tendon sheat (GCT-TS)
    Sinivite villonodulare pigmentosa (PVNS) / tumore a cellule giganti delle guainee tendinee
    E.1.1.1Medical condition in easily understood language
    Tumor of the tendon sheath
    Tumore delle guainee tendinee
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10062856
    E.1.2Term Giant cell tumour of tendon sheath benign
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to compare the response rate of PLX3397 with that of placebo per Response Evaluation Criteria in Solid Tumor, version 1.1 (RECIST 1.1) at week 25 in subjects with symptomatic, locally advanced PVNS or GCT-TS
    L'obiettivo primario dello studio ¿ confrontare, alla Settimana 25, il tasso di risposta di PLX3397 rispetto al placebo in soggetti con PVNS/GCT-TS sintomatico localmente avanzato, valutato secondo i Criteri di valutazione della risposta nei tumori solidi, versione 1.1 (Response Evaluation Criteria in Solid Tumors, RECIST 1.1).
    E.2.2Secondary objectives of the trial
    The secondary efficacy objectives are to evaluate: (i) patient-reported outcomes (PROs), including the Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale (NRS) item, Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function Scale, and Worst Stiffness NRS item, at week 25; (ii) response based on TVS at week 25; (iii) range of motion at week 25; and (iv) duration of response
    Gli obiettivi secondari di efficacia consistono nel valutare: (i) gli esiti riferiti dai pazienti (Patient-Reported Outcomes, PRO), comprese la voce "Peggior dolore" della Scala numerica per la misurazione del dolore (Numeric Rating Scale, NRS) del Breve inventario del dolore (Brief Pain Inventory, BPI), la Scala della funzionalit¿ fisica (Physical Function Scale, PFS) del Sistema di misurazione degli esiti riferiti dai pazienti (Patient-Reported Outcomes Measurement Information System, PROMIS) e la voce "Peggior rigidit¿" della scala NRS, alla Settimana 25; (ii) la risposta in base al Punteggio del volume tumorale (Tumor Volume Score, TVS) alla Settimana 25; (iii) l'escursione di movimento alla Settimana 25; e (iv) la durata della risposta.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Age =18 years.
    2.A diagnosis of PVNS or GCT-TS (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pahologist, and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a mutli-disciplinary tumor board).
    3.Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans by a central radiologist.
    4.Symptomatic disease because of active PVNS or GCT-TS. a. a worst pain of at least 4 at any time during the week preceding the Screening Visit (based on scale of 0 to 10, with 10 representing "pain as bad as you can imagine"). b. a worst stiffness of at least 4 at any time during the week preceding the Screening Visit (based on a scale of 0 to 10, with 10 representing "stiffness as bad as you can imagine").
    5.Stable prescription of analgesic regimen during the 2 weeks prior to randomization.
    6.During the 2 week prior to randomization, at least 4 of 7 consecutive days of BPI Worst Pain NRS items and Wirst Stiffness NRS items completed correctly.
    7.Women of childbearing potential must have a negative serum pregnancy test within the 14-day period prior to randomization. (Where demanded by local regulations, this test may be required within 72 hours of randomization).
    8.Males and females of childbearing potential are permitted in the study so long as they consent to avoid getting their partner pregnant or becoming pregnant, respectively, by using a highly effective
    contraception method, as described below, throughout the study and for up to 90 days after completion. Highly effective methods of contraception include: intra-uterine device (nonhormonal or hormonal), bilateral tubal occlusion, vasectomy, sexual abstinence, or barrier methods (e.g., condom, diaphragm) used in combination with hormonal methods associated with inhibition of ovulation. Women of nonchildbearing potential may be included if they are either surgically sterile or have been postmenopausal for = 1 year. Women who have documentation of at least 12 months of spontaneous amenorrhea and have an FSH level > 40 mIU/mL will be considered postmenopausal.
    9.Adequate hematologic, hepatic, and renal function.
    10.Willingness and ability to complete the BPI Worst Pain NRS item, Worst Stiffness NRS item, PROMIS Physical Function Scale, and other self-assessment instruments throughout the study.
    11.Willingness and ability to use a diary.
    12.Signature of Informed Consent Form, prior to any study-related procedures and to comply with all study requirements
    1. Età =18 anni.
    2. Pazienti con diagnosi di PVNS o GCT-TS (i) confermata istologicamente da un patologo che opera nel centro di trattamento o da un patologo centrale, (ii) per i quali la resezione chirurgica comporterebbe un potenziale peggioramento della limitazione funzionale o una grave morbilità (malattia localmente avanzata); la morbilità dovrà essere determinata consensualmente da personale qualificato (ad esempio, due chirurghi o un consiglio multidisciplinare per la valutazione dei tumori).
    3. Malattia misurabile come definita dal RECIST 1.1 (a meno che sia richiesta una dimensione minima di 2 cm), valutata da un radiologo centrale tramite scansioni MRI.
    4. Malattia sintomatica dovuta a PVNS/GCT-TS attivo, definita secondo una o più delle seguenti descrizioni:
    a. punteggio minimo di 4 nella voce "peggior dolore" in qualsiasi momento durante la settimana precedente alla Visita di screening (basato sulla scala di valutazione da 0 a 10, laddove 10 rappresenta il "peggior dolore immaginabile").
    b. punteggio minimo di 4 nella voce "peggiore rigidità" in qualsiasi momento durante la settimana precedente alla Visita di screening (basato sulla scala di valutazione da 0 a 10, laddove 10 rappresenta la "peggiore rigidità possibile").
    5. Prescrizione di regime analgesico stabile nelle 2 settimane precedenti alla randomizzazione.
    6. Corretta compilazione della voce "Peggior dolore" della NRS del BPI e della voce "Peggior rigidità" della NRS per almeno 4 su 7 giorni consecutivi delle due settimane precedenti alla randomizzazione.
    7. Le donne in età fertile devono presentare un test di gravidanza sul siero negativo entro 14 giorni dalla randomizzazione (ove previsto dalle normative locali, tale test può essere richiesto entro 72 ore dalla randomizzazione).
    8. Gli uomini e le donne in età fertile possono prendere parte allo studio a condizione che acconsentano ad evitare di procreare/iniziare una gravidanza adottando, durante la sperimentazione e fino a 90 giorni dopo la sua conclusione, uno dei seguenti metodi anticoncezionali altamente efficaci: contraccettivi ormonali associati all’inibizione dell’ovulazione, dispositivo intrauterino, sterilizzazione chirurgica (compresa vasectomia del partner) o astinenza sessuale. Le donne non fertili possono essere incluse se chirurgicamente sterili o in post-menopausa da =1 anno. Saranno considerate in post-menopausa le donne con amenorrea spontanea documentata di almeno 12 mesi che presentano un livello di ormone follicolo-stimolante >40 mIU/ml.
    9. Funzionalità renale, epatica ed ematologica adeguata, definita in base ai seguenti valori:
    • Conta assoluta dei neutrofili =1,5×109/l
    • Emoglobina >10 g/dl
    • Conta piastrinica =100×109/l
    • AST/ALT =1,5×ULN
    • Bilirubina totale =1,5×ULN
    • Creatinina sierica =1,5×ULN
    10. Volontà e capacità di compilare, durante lo studio, la voce "Peggior dolore" della NRS del BPI, la voce "Peggiore rigidità" della NRS, la Scala della funzionalità fisica del PROMIS e altri eventuali strumenti di autovalutazione.
    11. Volontà e capacità di usare un diario elettronico.
    E.4Principal exclusion criteria
    1. Investigational drug use within 28 days of randomization. 2. Previous use of pexidartinib or any biologic treatment targeting CSF-1 or the CSF1R; previous use of oral tyrosine kinase inhibitors, eg, imatinib or nilotinib, are allowed. 3. Active cancer (either concurrent or within the last year of starting study treatment) that requires non-surgical therapy (eg, surgical, chemotherapy or radiation therapy), with the exception of PVNS/GCT TS, adequately treated basal or squamous cell carcinoma of the skin, melanoma in-situ, or carcinoma in-situ of the cervix or breast, or prostate carcinoma with a prostate specific antigen value <0,2 ng/mL. 4. Known metastatic PVNS/GCT-TS. 5. Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or know active or chronic infection with human immunodeficiency virus. 6. Known active tuberculosis. 7. Significant concomitant arthropathy in the affected joint, serious illnes, uncontrolled infection, or a medical or psychiatric history that, in the investigator's opinion, would likely interfere with the person's study participation or the interpretation of his or her results. 8. Women who are breastfeeding. 9. A screening Fridericia corrected QT interval (QTcF) = 450 ms(men) or = 470 ms (women). 10. MRI contraindications. 11. History of hypersensitivity to any excipients in the investigational product.
    12. Inability to swallow capsules.
    1. Uso di un farmaco sperimentale nei 28 giorni precedenti alla randomizzazione;
    2. Uso precedente di pexidartinib o di qualsiasi trattamento biologico mirato al fattore di stimolazione delle colonie 1 (Colony Stimulating Factor 1, CSF-1) o al recettore del CSF-1; è ammesso l'uso precedente di inibitori orali della tirosin-chinasi, quali, ad esempio, imatinib o nilotinib.
    3. Tumore attivo (concomitante o insorto nell'anno precedente all'inizio del trattamento in studio) che richiede una terapia (ad esempio, chirurgica, chemioterapia o radioterapia), ad eccezione del carcinoma cutaneo a cellule basali o squamose adeguatamente trattato, del melanoma in situ, del carcinoma in situ della cervice o mammario, o del carcinoma prostatico con un valore di antigene prostatico specifico <0,2 ng/ml.
    4. PVNS/GCT-TS metastatico noto.
    5. Infezione nota attiva o cronica da virus dell'epatite B o C, o da virus dell'immunodeficienza umana.
    6. Tubercolosi attiva nota.
    7. Artropatia concomitante significativa a carico delle articolazioni interessate, malattia grave, infezione non controllata oppure anamnesi medica o psichiatrica che, a giudizio dello Sperimentatore, potrebbe compromettere la partecipazione allo studio di un candidato o l'interpretazione dei suoi risultati.
    8. Donne in allattamento.
    9. Intervallo QT corretto mediante la formula di Fridericia (QTcF) =450 ms (uomini) o =470 ms (donne) allo screening.
    10. Controindicazioni per la MRI.
    11. Anamnesi di ipersensibilità a uno degli eccipienti del prodotto sperimentale.
    12. Incapacità di ingoiare capsule.
    E.5 End points
    E.5.1Primary end point(s)
    The proportion of subjects who achive a complete or partial response at the week 25 visit based on centrally read MRI scans and RECIST 1.1.
    Percentuale di soggetti che raggiungono una risposta completa (Complete Response, CR) o parziale (Partial Response, PR) alla Visita della Settimana 25, sulla base di una valutazione eseguita tramite la lettura centrale delle scansioni MRI e i criteri RECIST 1.1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 25
    Settimana 25
    E.5.2Secondary end point(s)
    1. Proportion of responders based on the BPI Worst Pain NRS item and analgesic use by BPI-30 definition 2. Proportion of responders based on centrally evaluated MRI scans and TVS at the week 25 visit 3. Mean change from baseline in range of motion of the affectd joint, relative to a reference standard for the same joint, at the week 25 visit 4. Mean change from baseline score in the PROMIS Physical Function Scale at the Week 25 visit 5. Mean change from the baseline score in the Worst Stiffness NRS item at th week 25 visit 6. Duration of response (CR or PR) based on MRI and RECIST 1.1 7.Duration of response (CR or PR) based on MRI and TVS
    1. Percentuale di responder in base alla voce "Peggior dolore" della NRS del BPI e all'uso di analgesici secondo la definizione BPI-30 2.Percentuale di responder in base alla valutazione centrale delle scansioni MRI e al TVS alla Visita della Settimana 25 3. ¿ Variazione media alla Visita della Settimana 25 rispetto al basale nell'escursione di movimento dell'articolazione interessata rispetto ad uno standard di riferimento per la stessa articolazione 4.Variazione media alla Visita della Settimana 25 rispetto al basale nel punteggio della Scala della funzionalit¿ fisica del PROMIS 5.Variazione media alla Visita della Settimana 25 rispetto al basale nel punteggio della voce "Peggiore rigidit¿" della NRS 6.Durata della risposta (CR o PR) in base alla MRI e ai criteri RECIST 1.1. 7.Durata della risposta (CR o PR) in base alla MRI e al TVS
    E.5.2.1Timepoint(s) of evaluation of this end point
    week 25
    settimana 25
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Denmark
    France
    Germany
    Hungary
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 26
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 60
    F.4.2.2In the whole clinical trial 126
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who complete Part 2 will be eligible to continue for longer efficacy and safety follow-up or to enter a separate protocol to continue receiving PLX3397 until disease progression, unacceptable
    toxicity, or the occurrence of other termination criteria.
    I soggetti che completano la Parte 2 saranno elegibili per continuare per efficacia prolungata o per follow-up di sicurezza o per entrare in un protocollo separato per ricevere PLX3397 fino a che non vi sia progressione di malattia, tossicit¿ inaccettabile o la manifestazione di un altro criterio di terminazione.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-07-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-04-29
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA